Výsledky vyhledávání - "Sayeh Ben-Arieh"

A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance

Autor: Haim Biran, Dana Botser, Jair Bar, Nir Peled, Stephen Raskin, Rossie Navon, Amir Onn, Einav Nili Gal-Yam, Sayeh Ben-Arieh

Publikováno v: Journal of Clinical Oncology. 33:e19031-e19031

e19031 Background: mNSCLC pts benefit from EGFR TKI treatment. However, resistance inevitably occurs and is difficult to treat. We wanted to evaluate the efficacy of an ErbB-family inhibitor, afati...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83c56208c2b8bf0879492136cceb4dbf
https://doi.org/10.1200/jco.2015.33.15_suppl.e19031

Zobrazit plný text záznamu

Circulating ProGRP and tissue thyroid transcription factor 1 (TTF1) in small-cell lung carcinoma (SCLC) limited versus extensive stages

Autor: Victoria Doviner, Benny Nisman, Jair Bar, Sayeh Ben-Arieh, Nir Peled, Amir Onn, Haim Biran, Marina Perelman, Tamar Peretz

Publikováno v: Journal of Clinical Oncology. 32:e18555-e18555

e18555 Background: SCLC stage is classified as limited (LD) or extensive (ED). ED is incurable while LD patients may survive. Gastrin-releasing peptide (GRP), an SCLC autocrine growth factor, assay...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc5bb0c432c39aec0d518f9400d363f0
https://doi.org/10.1200/jco.2014.32.15_suppl.e18555

Zobrazit plný text záznamu

P2.23 First-Line Gefitinib in Epidermal Growth Factor Receptor Mutation-Positive (EGFR+) Non-Small Cell Lung Cancer (NSCLC) in an Israeli Cohort

Autor: Amir Onn, Haim Biran, Damien Urban, Raya Leibowitz-Amit, Daniel Keizman, Sayeh Ben-Arieh, Maya Gottfried, M. Mishaeli, N. Maimon

Publikováno v: Annals of Oncology. 23:v29

Background Reported response rates (RR) to 1st line gefitinib in advanced EGFR+ NSCLC range from 55 % to over 70 %. The primary goal of this retrospective analysis was to study the efficacy of gefitinib in the first line treatment of EGFR+ advanced N

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31836d21aafe9da4034d2a074442f3e7
https://doi.org/10.1016/s0923-7534(20)31346-6

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání